INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS: A CHOICE AND AN INDIVIDUAL APPROACH


如何引用文章

全文:

详细

Type 2 diabetes mellitus (DM2) is characterized by dangerous chronic complications, which lead to disability and reduction in the quality of life. Prevention of vascular complications of diabetes mellitus is an important task in modern medicine. In this regard, results of research on the target range of glycemic control in DM2 have a great importance. Optimal mechanism, the rate and degree of reduction of glycated hemoglobin in various categories of patients may be different. Early and reasonable administration of insulin, timely dose titration are crucial to the long-term maintenance of target blood glucose levels in patients with type 2 diabetes mellitus and provide numerous opportunities to achieve the main goals of treatment of DM - maintenance of long-term metabolic control and prevention or delay of vascular complications.

参考

  1. Дедов И.И., Шестакова М.В. Проблемы контроля качества диабетологической службы в России по данным на январь 2007 г. // Сахарный диабет. 2007. № 3. С. 55-57.
  2. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
  3. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
  4. Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998;14(15):439-45.
  5. Shim WS, Kim SK, Kim HJ. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006;155(4):615-22.
  6. O'Rahilly S, John Savill J. Science, medicine, and the future non-insulin dependent diabetes mellitus: the gathering storm. BMJ 1997;314(29):955-67.
  7. The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
  8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.
  9. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
  10. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
  11. Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 2008;358:2630-33.
  12. Gerstein HC, Miller ME, Byington RP. et al. ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
  13. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group.. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008;358:2560-72.
  14. Ray KK, Rao S, Seshasai K, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.
  15. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
  16. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
  17. Sheikh-Ali M, Chehade JM. Initiation of insulin therapy in older adults. Geriatrics and aging. 2009;12(3):135-40.
  18. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
  19. Дедов И.И., Шестакова М.В. Оптимизация и интенсификация инсулинотерапии при сахарном диабете 2 типа (клинические рекомендации) // Сахарный диабет. 2007. Спецвыпуск. С. 9-55.
  20. Robertson C. Physiologic insulin replacement in type 2 diabetes. Diabetes Educator 2006;3:423-32.
  21. DeWitt DE, Hirch IB. Outpatient insulin therapy in type 1 and 2 diabetes mellitus. JAMA 2003;289(17):2254-64.
  22. Hirsch Irl B Bergenstal RM, Parkin CG, et al. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 2005;2(23):78-86.
  23. Turner HE, Matthews DR. The use of fixed-mixture insulins in clinical practice. Eur J Clin Pharmacol 2000;56:19-25.
  24. White JR Jr, Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med 1997;101(2):58-70.
  25. Rizvi AA, Ligthelm RJ. The Use of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: advantages and limitations. Insulin 2007;2:68-79.
  26. Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9(5):630-39.
  27. Garber AJ. Premixed Insulin Analogues for the treatment of Diabetes Mellitus. Drugs 2006;66(1):31-49.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##